The discovery and development of new medicines that promote human health and potentially extend natural life remains a remarkably challenging endeavor. In this Commentary, we identify key elements of communication required to successfully translate promising biological findings to novel approved drug therapies and discuss the attendant challenges and opportunities.
While the successful development of numerous drugs to manage a wide variety of maladies has improved the quality and length of life for countless people, there remains a large unmet need for therapeutics for especially challenging diseases, including various cancers, cardiovascular disease, metabolic disorders, neurodegenerative diseases, psychiatric disorders, infectious diseases, and numerous genetic syndromes. What are the key factors that limit our ability to tackle these diseases with novel medicines? For one, disease biology is immensely complex, and despite an ever-increasing understanding of both basic and disease biology, our ability to identify the most relevant therapeutic targets and to discover drugs that selectively, effectively, and safely modulate those targets to produce clinical benefit remains frustratingly limited. Furthermore, recent advances in the various ''omic'' technologies that enable precise molecular characterization of diseased tissue have revealed substantial inter-patient heterogeneity, prompting efforts to ''personalize'' drug treatment. This new paradigm presents both an opportunity to match patients with the right medicines as well as the challenge to develop a sufficiently diverse arsenal of drugs to benefit the growing number of subsets of biomarker-stratified patients.
There is also the challenge of the drug discovery and development process itself-a byzantine and expensive undertaking that fails far more often than it succeeds. A typical program, culminating with regulatory approval, involves dozens to hundreds of workers, requires 10-15 years, and costs hundreds of millions of dollars (DiMasi et al., 2016) . Several recent trends have converged to highlight the role of effective, forthright communication among the many participants in this process as an important element of success.
While the discovery and development of currently approved drugs has proceeded through various paths, a somewhat standard approach underlies most successful programs (Figure 1 ). Typically, a drug discovery campaign begins with a biological observation and an associated therapeutic hypothesis. In most cases, the identification of such targets reflects the cumulative findings of multiple investigators whose independent efforts eventually converge. However, even a single especially provocative discovery can prompt efforts to prosecute a target for therapeutic development. Initial findings are usually reported by academic researchers in peer-reviewed publications, and the especially promising reports prompt efforts to further validate the target and the therapeutic hypothesis.
Once a promising target is deemed ''validated,'' it is often prosecuted for drug discovery. The development of high-throughput screening approaches and improvements in medicinal chemistry and antibody engineering methods in the 1980s and 1990s have revolutionized the pharmaceutical industry, greatly enabling the discovery of candidate therapeutic molecules. The underlying technology has moved beyond pharmaceutical companies, and screening is also now conducted (usually on a smaller scale) in many academic research institutions, with academic laboratories pursuing efforts to discover drugs-or at least ''tool compounds'' to serve as potential starting points for drug development. Such efforts have yielded numerous tantalizing publications as well as many licensing agreements between academic institutions and biopharmaceutical companies.
Unfortunately, many of the published claims regarding candidate therapeutic targets and ''lead compounds'' prove problematic. In a revealing study, Amgen scientists described their efforts to replicate results from dozens of landmark cancer research publications (Begley and Ellis, 2012) . The result was disappointing-findings could be replicated in only six of 53 cases. While this was surprising to many, our experience as industry scientists and that of many of our colleagues has been similar. A number of root causes and contributing factors have been suggested, and they continue to be widely discussed. In any event, a basic failure of scientific communication was made plain by this experiment.
The ensuing discussion of these issues has been generally productive. While some changes in the manuscript review process have been implemented, it is too early to assess the impact. One approach, implemented by some journals, is a checklist for authors of life sciences articles intended to document the rigor with which experiments were conducted, including statistical methods and measures taken to address potential bias (Nature Editors, 2013; see also checklist available at: http://www.nature. com/authors/policies/checklist.pdf). The editors of some journals have also indicated a willingness to commission statisticians as consultants for certain manuscripts-noting that the training of young biologists is often inadequate with regard to statistics and quantitative analysis, potentially resulting in invalid conclusions.
In the context of drug discovery reports, especially those coming from academic biologists, many of whom underestimate the rigorous evaluation required to adequately credential a novel pharmacologic agent, journal editors should routinely engage industry-based scientists with relevant technical expertise to review such studies. This would be analogous to the aforementioned enhanced use of statisticians as consultants in the review process. One reason why industry reviewers are particularly attentive to robustness is their recognition of the cost of all-too-frequent clinical development failures.
Prior to publication, even at the early stages of a drug discovery project, academic biologists should be encouraged to seek guidance from technical experts. While soliciting consultation from industry scientists is likely to be challenging, many experts with relevant knowledge are in fact embedded within most academic biomedical research institutions these days. Notably, academic technology transfer departments within these institutions have a clear incentive to foster such interactions, considering their interest in developing and licensing intellectual property resulting from drug discovery projects. In our experience, industry reviewers of such licensing opportunities often uncover flaws that were perhaps missed by journal reviewers and the investigators themselves.
More fundamentally, communicating information regarding novel candidate targets and therapeutics in journal articles can be problematic because many claims are simply ''oversold,'' with authors failing to note potential caveats, or other limitations of their analysis. Contributing factors include a peer-review journal publication process that sometimes favors luster over rigor, the evolving NIH mission that increasingly emphasizes translational potential, as well as the occasionally blind optimism that characterizes human nature. However, considering the importance of these target and drug discoveries in the future development of medicines to address important human diseases, additional scrutiny is appropriate before such claims are published. We also suggest that published claims regarding novel targets or inhibitors should include specific communication regarding potential caveats. Journal editors should consider mandating that the Discussion section of such reports includes an honest and complete listing of these limitations. Such ''disclaimers'' should not preclude publication (unless the limitations are substantial), but rather, they should set a realistic foundation for the next important steps in the process of adequately credentialing and validating a candidate target or molecule. In short, the benefit of an enhanced process for manuscript review and publication to improve communication of genuine biomedical advances with the potential to provide a foundation for eventual drug development seems clear.
The drug discovery paradigm itself introduces a variety of communication challenges. Typically, once a target is validated, a project team is formed within a biotechnology or pharmaceutical company to initiate the laborious process of discovering and evaluating candidate molecules with therapeutic potential. Teams include biologists, medicinal chemists, biochemists, structural biologists, pharmacologists, safety toxicologists, clinicians, and marketing professionals. This group is charged with oversight of a carefully orchestrated effort involving various technical functions. Although they share a common goal, each of the experts on the team is, in some measure, a ''specialist,'' having trained for many years to develop competence in an arcane discipline. The biologists talk of ''membrane blebs'' and ''mitotic catastrophe,'' chemists describe ''chiral centers'' and ''rotational bonds,'' structural biologists refer to ''steric hindrance'' and ''NMR spectroscopy,'' biochemists speak of ''Hill coefficients'' and ''non-competitive inhibition,'' pharmacologists relate to ''bioequivalence'' and ''hepatic clearance,'' toxicologists make note of ''exposure limits'' and ''genotoxicity,'' and clinicians describe ''marrow suppression'' and ''edema.'' In short, the various team members each speak a different ''language,'' and unlike at a United Nations meeting, there is usually no interpreter at the table.
Given the high level of specialization among the participants, the drug discovery paradigm faces an inherent communication challenge, operating against a backdrop of the innumerable decisions required of project teams. We suggest that team experts make a concerted effort to describe vital information using language that is readily understandable to everyone on the team. A conscious effort should be made to avoid jargon. It is neither necessary nor practical that everyone on the team understands all the technical nuances of each discipline, and use of jargon often bundles assumptions in a ''short-hand'' that can obscure the essential points for others. The most effective project teams use their shared On the left, the various steps involved in a typical drug development program are described, beginning with the early discovery and reporting of candidate therapeutic targets or pharmacologic agents and culminating with regulatory drug approval and clinical implementation. On the right, some of the key challenges associated with each step in this process are briefly described.
understanding, facilitated by genuine efforts to develop a common and informative language, to enable optimal decision-making. By engaging all the key participants, a conscious effort at clear, forthright communication is thus likely to increase the chance of program success.
If we consider drug discovery as an engineering problem-which to a large degree it is-we can examine the role of communication in the context of other ambitious engineering feats. Putting a man on the moon required that teams of highly specialized aeronautical, mechanical, electrical, chemical, and computer engineers carefully coordinated their activities to ensure mission success. A failure to appropriately link these functions could be catastrophic. And while a communication breakdown due to ''language'' differences could be problematic, other forms of miscommunication among scientists and between scientists and managers can also play a role. In fact, NASA has substantial experience in this area, as their many ambitious programs were not uniformly successful. For example, the Apollo 13 explosion was ultimately attributed to a series of poor communications between engineers and managers that led to some bad decisions before the mission even began. Similar communication problems contributed to the two space shuttle disasters, the flawed Hubble telescope construction, and the infamous metric conversion error that doomed the Mars Orbiter. By analogy, the successful ''engineering'' of a new drug depends critically on effective communication of innumerable bits of information among a large number of experts and managers, and includes an ever-present risk of catastrophic failure.
One noteworthy distinction between drug discovery programs and more conventional engineering projects relates to the role and magnitude of the attendant uncertainty. Putting a man on the moon should not have required good luckrather, it required accurate calculations and quantitative measurements of wellunderstood physical systems. Biology, on the other hand, is still very much incompletely understood, and the result of various perturbations of biological systems remains largely unpredictable. Consequently, much of our new knowledge is determined empirically. As such, in the iterative trial-and-error process that underlies much of biology discovery, communicating experimental failure can be just as important as communicating success.
Moving beyond the discovery of candidate drugs, the drug development process required to evaluate the clinical potential of a novel drug candidate is similarly associated with communication challenges. Appropriate scrutiny at an early stage should translate into a greater probability of future success. Surprisingly, however, a recent analysis of AstraZeneca's drug development pipeline revealed that, among the projects classified as efficacy failures in Phase II, 40% were associated with a fundamental failure to link the supposed molecular target to the intended indication (Cook et al., 2014) . Many such failures could probably have been avoided by focusing at an early stage on issues such as the strength of the evidence supporting the drug target, adequate pharmacodynamics measures, and robust activity in a well-validated animal model, and ensuring that all of the relevant information was clearly communicated among project team members.
Evidence of failed communication was implied in another finding from the AstraZeneca analysis-development plans targeting the wrong patient population were cited as a reason for failure to demonstrate clinical efficacy in a third of cases. The authors suggested that some teams may have overvalued commercial considerations relative to targeting the most appropriate patient populations based on the underlying disease biology. One example is the development of olaparib, a PARP inhibitor originally shown to confer synthetic lethality in cancer cells with BRCA1 or BRCA2 mutations (Bryant et al., 2005) . Despite the obvious clinical development path informed by early results in patients with BRCA mutations, later clinical development focused on a much larger (and more heterogeneous) population that was not selected on the basis of BRCA mutations, and the inhibitor failed to demonstrate sufficient efficacy. Clinical development in BRCA-deficient tumors ultimately continued and proved highly efficacious after an unfortunate delay, and the drug is now approved. We suggest that a focus on translational biology and forthright communication of the therapeutic hypothesis by the project team might have avoided the delays and expense that resulted from targeting the wrong patient population.
Central to the drug development enterprise is the need to translate the underlying biological discovery into a relevant patient population. Use of the word ''translate'' in this context implies the challenge of effectively communicating the potential impact of basic biomedical discoveries so that therapies on which they are based can be effectively evaluated in humans. The terms ''translational biology'' and ''translational medicine'' suggest that more than one language is being spoken and highlights the need for a core understanding. Indeed, the National Center for Advancing Translational Science (NCATS; http://www.ncats.nih.gov/about) was established within the NIH to ''transform the translational science process so that new treatments and cures for disease can be delivered to patients faster'' (Collins, 2011) . A key part of the mission is to ensure training and education that focuses on team-based, interdisciplinary science outside of traditionally-defined fields. It appears that momentum is gathering to develop future researchers who are well versed in the core translational curriculum. Such individuals will make up the next generation of drug developers, and will hopefully develop a lingua franca that will facilitate communication more deeply and intuitively than a mere attempt at ''translation. '' We believe that success of ''precision medicine'' will depend on developing and rewarding similar competencies among biomedical scientists and physicians. In the IOM report, ''Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease,'' the authors note that the new system will require that healthcare providers develop great literacy in the interpretation and application of molecular data and that biomedical education will need to adjust to accommodate this emerging need (Committee on a Framework for Development a New Taxonomy of Disease, 2011 ). An example cited by the authors is a system characterized by vertical integration of biomedical information rather than disciplinespecific training. The goal would be to have future physicians develop a holistic view of biological processes, one that prepares them to successfully integrate genomics with a new taxonomy of disease and promotes far more informed decision-making in clinical practice. A fundamental change in medical education of this type would have the additional benefit of preparing students pursuing research careers to function in a biomedical milieu that increasingly requires multidisciplinary approaches.
Realizing the full benefits of precision medicine in drug development will require an integrated approach to communicating genuine discoveries as well as more prosaic results. Ensuring an appropriate degree of scientific rigor in disseminating key discoveries is ongoing, but institutional barriers and biases that tend to discourage publishing negative data and confirmatory data still exist. Some progress toward openness has come in the form of a commitment by several pharmaceutical companies to make available raw clinical trial data for exploratory analyses by third-party researchers (http:// www.phrma.org/phrmapedia/responsibleclinical-trial-data-sharing). Regulatory agencies, including the FDA, have expressed enthusiasm for enhanced communication with drug sponsors to improve the efficiency of the drug development process (U.S. Department of Health and Human Services, 2015) . The FDA regularly provides advice on the adequacy of technical data in support of an IND filing, design of a clinical trial, and the information needed to meet regulatory requirements. For drugs developed under expedited programs, the FDA offers more intensive guidance with increased interactions and communications, including meetings.
In the final analysis, the biomedical community must communicate effectively with the public at large. Given the enormous public investment in drug development, together with the high cost of new treatments, the public has a right to understand and question current practices. When people seek to build a bridge or even send someone to the moon, they do not envision a process that succeeds only rarely! Many are dismayed by the seemingly feeble pace of progress in developing treatments for many common diseases. It will certainly require our collective communication skills to explain the disappointing reality that so many expensive drug development efforts are viewed simply as ''shots on goal.'' A solid scientific hypothesis, thoughtful decision-making, and high-quality experimental execution are generally regarded as essential components of any successful drug development campaign. However, because much of biology remains poorly understood, even when we believe that we have mitigated the potential risks associated with a new investigational agent to the best of our abilities, it is well understood that the outcome of clinical experimentation is unpredictable, and in most cases, development unfortunately fails. Good fortune notwithstanding, we suggest that effective communication among the many participants throughout the long course of this complex process is yet another important element, and one for which some relatively straightforward steps could be taken to make significant improvements and thereby increase the likelihood of success for these vitally important programs.
